Serial sodium values and adverse outcomes in heart failure with preserved ejection fraction. (1st September 2019)

• Record Type: Journal Article
• Authors: Imran, Tasnim F.; Kurgansky, Katherine E.; Patel, Yash R.; Orkaby, Ariela R.; McLean, Robert R.; Ho, Yuk-Lam; Cho, Kelly; Gaziano, J. Michael; Djousse, Luc; Gagnon, David R.; Joseph, Jacob
• Is Part Of: International journal of cardiology. Volume 290(2019)
• Page Start: 119
• Page End: 124
• Publication Date: 2019-09-01
• Subjects: Heart failure with preserved ejection fraction -- Serum sodium -- Outcomes -- Mortality -- Hospitalization -- Heart failure hospitalization; Cardiology -- Periodicals; Electronic journals; 616.12
• DOI: 10.1016/j.ijcard.2019.03.040
• Languages: English
• ISSNs: 0167-5273

Abstract

Abstract: Objective: The purpose of our study is to examine whether serial measurements of serum sodium values after diagnosis identify a higher-risk subset of patients with heart failure with preserved ejection fraction. Methods: We identified 50, 932 subjects with HFpEF with 759, 577 recorded sNa measurements (mean age 72 ± 11 years) using a validated algorithm in the VA national database from 2002 to 2012. We examined the association of repeated measures of sNa with mortality using a multivariable Cox proportional hazards model. Results: After a median follow-up of 2.9 years (IQR: 1.2–5.4), 19, 011 deaths occurred. After adjusting for age, sex, race, BMI, glomerular filtration rate, potassium, coronary artery disease, hypertension, hyperlipidemia, atrial fibrillation, pulmonary disease, diabetes, anemia, and medications, we found J-shaped associations of serum sodium with mortality. HRs for all-cause mortality were 2.48 (95% CI: 2.38–2.60) for the sNA 115.00–133.99 category; and 1.40 (95% CI: 1.35–1.46) for the sNA 143.00–175.00 category compared to the 137.01–140.99 category (ref). We used generalized estimating equation-based negative binomial regression to compute the incidence density ratios (IDR) to examine days hospitalized for heart failure and for all causes. There were a total of 1, 275, 614 days of all-cause hospitalization and 104, 006 days of heart-failure hospitalization. The IDRs for the lowest sNA group were 2.03 (95% CI: 1.90–2.18) for all-cause hospitalization and 1.73 (95% CI: 1.39–2.16) for heart-failure hospitalization. Conclusions: Our findings suggest that monitoring of serum sodium values during longitudinal follow-up can identify HFpEF patients at risk of adverse outcomes. Highlights: A J-shaped association exists between serial serum sodium measurements and major adverse outcomes in HFpEF. Low serum sodium measurement recorded at any time after HFpEF diagnosis is associated with a higher risk of adverse outcomes. This association could be secondary to neurohormonal activation in HFpEF.